CYDY - CytoDyn May Be One Of The First Biotechs To Have A Drug That Helps Against Covid-19
The respiratory condition that is so dangerous in Covid-19 results from a condition called a "cytokine storm." CytoDyn (CYDY) believes that filling the CCR5 receptor with a harmless monoclonal body will prevent further damage.
CytoDyn reported on March 19 that its main drug candidate, leronlimab, was given IND status by the FDA for use in two Covid-19 patients in New York City.
On March 23, CytoDyn announced that additional two patients have been given leronlimab, bringing the total to four patients.
Today, March 27, the company has revealed the initial results of the use of